Detailed instructions for neratinib/neratinib (He Li'an)

Neratinib (Neratinib, trade name Nerlynx, Chinese name: He Li'an, neratinib, neratinib maleate tablets) is an oral small molecule irreversible pan-HER receptor tyrosine kinase inhibitor. As an important part of the HER2 targeted therapy sequence, it is regarded as a new generation of targeted drugs after Trastuzumab and Pertuzumab. Neratinib blocks the growth and proliferation signals of tumor cells from the source by simultaneously inhibiting the HER1 (EGFR), HER2 and HER4 signaling pathways, providing longer-term disease control possibilities for HER2-positive breast cancer patients.

1. Indications and clinical uses

Neratinib was initially approved for extended adjuvant treatment in patients with early-stage HER2-positive breast cancer who have received adjuvant trastuzumab.It is intended to reduce the risk of disease recurrence. Clinically, it is often used as an oral maintenance medication after trastuzumab treatment to provide further targeted inhibition and prolong disease-free survival for patients who have completed one year of trastuzumab treatment. In addition, in advanced or metastatic breast cancer, the combination of neratinib and capecitabine has been proven to be active in HER2-positive patients who have failed multiple lines of treatment and can improve tumor control rate and quality of life.

2. Usage and dosage adjustment

Prior to the use of neratinib, clinical guidelines recommend preventive antidiarrheal management, especially during the first two months of treatment. The recommended dose for adults is 240 mg orally daily (6 40 mg tablets), taken with meals. For advanced patients, it can be used in conjunction with capecitabine, following a 21-day cycle schedule: neratinib is 240 mg daily for 21 consecutive days, and capecitabine is taken orally twice a day for the first 14 days, and the dose is calculated based on body surface area.

Some patients can use a dose escalation strategy to improve tolerance: 120 mg daily in the first week, 160 mg in the second week, and 240 mg in the third week and thereafter. If obvious toxicity or adverse reactions occur, the dose can be gradually reduced to 200mg, 160mg or 120mg/day. For patients with severe hepatic impairment (Child-Pugh class C), the recommended starting dose is reduced to 80 mg. When the drug is combined with antacids or H2 antagonists, attention should be paid to the dosage interval to avoid affecting absorption.

3. Pharmacological mechanism and principle of action

Neratinib binds irreversiblyThe intracellular tyrosine kinase domain of HER family receptors continuously inhibits its autophosphorylation process, thereby blocking the downstream MAPK and PI3K/AKT signaling pathways and inhibiting tumor cell proliferation and survival. Compared with reversible inhibitors, neratinib shows higher inhibitory intensity on HER2 mutant cell lines, and its active metabolites M3, M6, M7, and M11 also have synergistic anti-tumor effects. Animal models show that oral neratinib can significantly inhibit the growth of HER2-overexpressing tumors, suggesting its core value in HER2 signaling-dependent cancers.

4. Adverse reactions and management suggestions

The most common adverse reaction during neratinib treatment is diarrhea, which usually occurs in the first few weeks of treatment. Therefore, it is recommended to combine antidiarrheal drugs (such as loperamide) for preventive treatment starting from the first dose. Other common adverse reactions include nausea, abdominal pain, rash, fatigue, vomiting, decreased appetite, and elevated liver enzymes. Some patients may experience dry skin, stomatitis or mild weight loss, and most of these symptoms can be alleviated through symptomatic treatment and dose adjustment. For patients treated with combined capecitabine, attention should also be paid to compound adverse events such as bone marrow suppression, fatigue, and hand-foot syndrome. If toxicity of grade 3 or above occurs, the medication should be suspended and the dose should be reduced or discontinued as directed after recovery.

5. Storage and drug stability

Neratinib should be storedin a dry environment at 20°C to 25°C, with short-term fluctuations between 15°C and 30°C allowed. Avoid freezing or exposure to moisture as this may affect the effectiveness of the medicine. Medications should be stored away from children and should be used within the specified validity period after opening.

Reference materials:https://en.wikipedia.org/wiki/Neratinib